127.  Adjei, AA, Reid, JM, Erlichman, C, Sloan, JA, Pitot, HC, Alberts, SR, Goldberg, RM, Hanson, LJ, Ruben, S, Boerner, SA, Atherton, P, Ames, MM, Kaufmann, SH. A Phase I and Pharmacologic Study of Pyrazoloacridine (NSC 366140) and Carboplatin in Patients with Advanced Cancer. Investigational New Drugs, Vol. 20: pp 297-304: 2002.

126.  Cuddihy, MT, Gabriel, SE, Sloan, JA, Crowson, CS, Melton, LJ. Osteoporosis Health Beliefs Among Postmenopausal Women With a History of Distal Forearm Fracture. Clinical Journal of Women's Health, Vol. 2, No. 2: pp 79-87: June 2002.

125.  Lobchuk, MM, Kristjanson, L, Degner, L, Blood, P, Sloan, JA. Wahrenehmung der symptombelastung bei lungenkrebspatieten: I. Ubereinstimmung zwischen patienten und den sie hauptsahlich pflegenden angehorigen. Pflege 12: pp 352-361.

124.  Schroeder, G, Sloan, JA, Cha, S, Atherton, P, Allmer, C, Erlichman, C. Phase I Oncology Clinical Trials for Related Subpopulations: The Power Walk Design. Drug Information Journal, Vol. 36: pp 581-593: 2002.

123.  Graham, D, Sloan, JA, Hillman, S, Fishkoff, S, Krook, JE, Okuno, SH, Mailliard, JA, Fitch, TR, Addo, F. A Phase II Study of the Dolastatin 15 Analogue LU 103793 in the Treatment of Advanced Non Small Lung Cancer. American Journal of Clinical Oncology, 2002.

122.  Erlichman, C, Sloan J. A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin. (In press, 2002). Annals of Oncology.

121.  Loprinzi, CL, Sloan, JA, Perez, EA, Quella, SK, Stella, PJ, Mailliard, JA, Halyard, MY, Pruthi, S, Novotny, PJ, Rummans, TA. Phase III evaluation of Fluoxetine for treatment of hot flashes. Journal of Clinical Oncology, Vol. 20, No. 6: pp 1578-1583: March 15, 2002.

120.  Varricchio, CG, Sloan, JA. The need for and characteristics of randomized, Phase III trials to evaluate symptom management in patients with Cancer. Editorial, Journal of the National Cancer Institute, Vol. 94, No. 16, pp 1184-1185: Aug. 21, 2002.

119.  Callstrom MR, Charboneau JW, Goetz MP, Rubin J, Wong GY, Sloan JA, Novotny PJ, Lewis BD, Welch TJ, Farrell MA, Maus TP, Lee RA, Reading CC, Petersen IA, Pickett DD. Painful metastases involving bone: feasibility of percutaneous CT- and US-guided radio-frequency ablation. Radiology 224: 87-97, 2002.

118.  Barton, D.L., Sloan, J.A., Zahasky, K.M., Smith, D.R., Pruthi, ., Novotny, P.J., Perez, E.A., Christensen, B.J. Pilot Evaluation of Gabapentin for Treating Hot Flashes. Mayo Clinic Proceedings. Press 2002.

117.  Symonds T, Berzon R, Marquis P, Rummans T, Sloan, JA, and the Clinical Significance Consensus Meeting Group. Clinical Significance of Quality of Life results: practical considerations for specific audiences. Mayo Clinic Proceedings 77: 572-583, 2002

116.  Sprangers MAG, Moinpour CM, Mayniham TJ, Patrick DL, Revicki DA, Sloan, JA, and the Clinical Significance Consensus Meeting Group. Assessing Meaningful Changes in Quality of Life Over Time: A User’s Guide for Clinicians. Mayo Clinic Proceedings 77: 561-571, 2002.

115.  Benrud-Larson LM, Dewar MS, Sandroni P, Rummans T, Haythornwaite JA, Low P. Quality of life in patients with postural tachycardia syndrome. Mayo Clinic Proceedings 77: 531-537, 2002.

114.  Cella, D, Bullinger, M, Scott, C, Barofsky, I, Sloan, JA, and the Clinical Significance Consensus Meeting Group. Group vs Individual Approaches to Understanding the Clinical Significance of Differences or Changes in Quality of Life. Mayo Clinic Proceedigs, April, 2002: pp 384-392.

113.  Guyatt, GH, Osoba, D, Wu, AW, Wyrwich, KW, Norman, GR, Sloan, JA, and the Clinical Significance Consensus Meeting Group. Methods to Explain the Clinical Significance of Health Status Measures. Mayo Clinic Proceedings, April, 2002: pp 371-383.

112.  Frost, MH, Bonomi, AE, Estwing-Ferrans, C, Wong, GY, Hays, RD, Sloan, JA, and the Clinical Significance consensus Meeting Group. Patient, Clinician and Population Perspectives on Determining the Quality of Life Scores. Mayo Clinic Proceedings, May 2002: pp 488-494.

111.  Sloan, JA, Aaronson, N, Cappelleri, JC, Fairclough, DL, Varricchio, C, Clinical Significance Consensus Meeting Group. Assessing the Clinical Significance of Single Items Relative to Summated Scores. Mayo Clinic Proceedings May, 2002: pp 479-487.

110.  Sloan, JA, Goldberg RM, Sargent DJ, Vargas-Chanes D, Nair S, Cha SS, Novotny PJ, Poon MA, O'Connell MJ, Loprinzi CL. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. Journal of Clinical Oncology, Vol. 20, No. 6: pp 1491-1498; March 15, 2002.

109.  Loprinzi, CL, Sloan, JA, Perez, EA, Quella, SK, Stella, PJ, Mailliard, JA, Halyard, MY, Pruthi, S, Novotny, PJ, Rummans, TA. Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes. Journal of Clinical Oncology, Vol. 20, No. 6, March 15, 2002 pp 1578-1583.

108.  Sloan, JA, Goldberg, RM, Sargent, DJ, Vargas-Chanes, D, Nair, S, Cha, SS, Novotny, PJ, Poon, MA, O'Connell, MJ, Loprinzi, CL. Women Experience Greater Toxicity with Fluorouracil-Based Chemotherapy for Colorectal Cancer. Journal of Clinical Oncology, Vol. 20, No. 6, March 15, 2002: pp 1491-1498

107.  Adjei, AA, Reid, JM, Diasio, RB, Sloan, JA, Smith, DA, Rubin, J, Pitot, HC, Alberts, ST, Goldberg, RM, Hanson, LJ, Atherton, P, Ames, MM, Erlichman, C. Comparative Pharmacokinetic Study of Continuous Venous Infusion Fluorouracil and Oral Fluorouracil with Eniluracil in Patients with Advanced Solid Tumors. Journal of Clinical Oncology, Vol. 20, No. 6, March 15, 2002: pp 1683-1691.

106.  Sloan JA, Cella D, Frost M, Guyatt GH, Sprangers M, Symonds T, Clinical Significance Consensus Meeting Group. Assessing Clinical Significance in Measuring Oncology Patient Quality of Life: Introduction to the Symposium, Content Overview, and Definition of Terms. Mayo Clinic Proceedings; April 2002; 367-370.

105.  Sloan JA, Sargent DJ, Lindman J, Allmer C, Vargas-Chanes D, Creagan ET, Bonner JA, O'Connell MJ, Dalton RJ, Rowland KM, Brooks BJ, Laurie JA. (2002) A new graphic for quality adjusted life years (Q-TWIST) survival analysis: The Q-TWIST plot. Quality of Life Research 11:37-45.

104.  Swensen SJ, Jett JR, Sloan JA, Midthun DE, Hartman TE, Sykes AM, Aughenbaugh GL, Zink FE, Hillman SL, Noetzel GR, Marks RS, Clayton AC, Pairolero PC. Screening for Lung Cancer with Low-Dose Spiral Computed Tomography (2002) American Journal Respiratory Critical Care Med. 165;508-513.

103.  Aminah J, Yamashita J, Sloan JA, Novotny PJ, Windschitl HE, Loprinzi CL. Does Megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation. (2002) 10:71-75

102.  Colon-Otero G, Niedringhaus RD, Hillman SH, Geyer S, Sloan JA, Krook JE, Windschitl HE, Marks RS, Wiesenfeld M, Tschetter LK, Jett J. A Phase II ^rial of Edatrexate, Vinblastine, Adriamycin, Cisplastin, and Filgrastim (EVAC/G-CSF) in Patients with Non-small Cell Carcinoma of the Lungs. American Journal of Clinical Oncology 2001 24(6): 551-555.

101.  Barton, D, LaVasseur, B, Loprinzi, C, Novotny, P, Wilwerding, MB, Sloan, JA. Venlafaxine for the Control of Hot Flashes: Results of a Longitudinal Continuation Study. Oncology Nursing Forum, 2002, Vol. 29, No. 1, 33-40

100. Jatoi, A, Windshitl, HE, Loprinzi, CL, Sloan, JA, Dakhil, SR, Mailliard, JA, Pundaleeka, S, Kardinal, CG, Fitch, TR, Krook, JE, Novotny, PJ, Christensen, B. Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology, 2002, Vol. 20, No. 2; 567-573.

99. Sloan, JA Asking the obvious Questions Regarding Patient Burden. Journal of Clinical Oncology, 2002; 20:4-6

98. Sloan, JA, Loprinzi, CL, Novotny, PJ, Barton, DL, Lavasseur, BI, Windschitl, H. (2001) Methodologic lessons learned from hot flash studies. Journal of Clinical Oncology, 19:4280-4290.

97. Sanderson CL, Sloan JA, Patten CA, Bonner JA, Geyer SM, McGinnis WL, Stella PJ, Marks RS. (Accepted 2001) Smoking behavior change of 226 patients with newly diagnosed stage IIIA/IIIB non-small cell lung cancer. Journal of Pain and Symptom Management.

96. Sloan JA, Loprinzi CL, Laurine JA Novotny PJ, Vargas-Chanes D, Krook JE, O’Connell MJ, Kugler JW, Tirona MT, Kardinal CG, Wiesenfeld M, Tschetter LK, Hatfield AK, Schafer PL. (2001). A simple stratification factor prognostic for survival in advanced cancer: The Good/Bad/Uncertain index. Journal of Clinical Oncology 19:3539-3546.

95. O’Rourke DJ, Klaasen KS, Sloan JA. (2001). Redesigning nighttime care for personal care residents. Journal of Gerontological Nursing 27:30-37.

94. Sloan JA, Atherton P, Reid J, Pitot HC, Erlichman C, Schaaf L. (2001). Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide. Cancer Chemother Pharmacol 48:241-249.

93. Galanis E, Goldberg R, Reid J, Atherton P, Sloan JA, Pitot H, Rubin J, Adjei AA, Burch P, Safgren SL, Witzig TE, Ames MM, Erlichman C. (2001). Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2’-deoxyuridine (IdUrd). Annals of Oncology 12:701-707.

92. Jatoi A, Loprinzi CL, Sloan JA, Klee GG, Windschitl HE, O’Connell M. (2001). Neuropeptide Y, Leptin, and Cholecystokinin 8 in patients with advanced cancer and anorexia: A North Central Cancer Treatment Group Investigation. Cancer 92:629-633.

91. Erlichman C, Adjei AA, Alberts SR, Sloan JA, Goldberg RM, Pitot HC, Rubin J, Atherton PJ, Klee GG, Humphrey R. (2001). Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Annals of Oncology 12:389-395.

90. Sloan JA, Tolman DE, Anderson JD, Sugar AW, Wolfaardt JF, Novotny P. (2001). Patients with reconstruction of craniofacial or intraoral defects: Development of instruments to measure quality of life. The International Journal of Oral and Maxillofacial Implants 16:225-245.

89. Sloan JA, Varricchio C. (2001). Quality of life endpoints in prostate chemoprevention trials. Urology 57:235-240.

88. Lee JJ, Lieberman R, Sloan JA, Piantadosi S, Lippman S. (2001). Design considerations for efficient prostate cancer chemoprevention trials. Urology 57:205-212.

87. Dudgeon DJ, Kristjanson L, Sloan JA, Lertzman M, Clement K. (2001). Dyspnea in cancer patients: Prevalence and associated factors. J Pain Symptom Manage 21:95-102.

86. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny PJ, Dakhil SR, Rodger K, Rummans TA. (2000). Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356:2059-2063.

85. Rummans TA, Bostwick JM, Clark MM (For the Mayo Clinic Cancer Center Quality of Life Working Group). (2000). Maintaining quality of life at the end of life. Mayo Clinic Proceedings 75:1305-1310.

84. Alberts SR, Erlichman C, Sloan JA, Okuno SH, Burch PA, Rubin J, Pitot HC, Goldberg RM, Adjei A, Atherton PJ, Kaufmann SH. (2001). Phase I trial of gemcitabine and CPT-11 given weekly for 4 weeks every 6 weeks. Annals of Oncology 12:627-631.

83. Niedringhaus RD, Hillman S, Geyer S, Sloan JA, Krook JE, Windschitl H, Marks R, Wiesenfeld M, Tschetter L, Jett JJ. (To appear 2000). A phase II trial of Edatrexate, Vinblastine, Adriamycin, Cisplatin and Filgrastim (EVAC/G-CSF) in patients with advanced non-small cell carcinoma of the lungs: A North Central Cancer Treatment Group Trial. To appear in Journal of Clinical Oncology.

82. Sloan JA, Bonner JA, Hillman SL, Allmer C, Shanahan TG, Brooks BJ, Marks S, Vargas D, Jett JR. (2002). A quality-adjusted re-analysis of a phase III trial comparing once-daily thoracic radiation versus twice-daily thoracic radiation in patients with limited stage small cell lung cancer. Journal of Clinical Oncology 52:371-381.

81. Jatoi A, Kumar S, Sloan JA, Nguyen PL. (2000). The Art of Oncology: When the Tumor is not the Target On Appetite and Its Loss. Journal of Clinical Oncology 18:2930-2932.

80. Pitot HC, Goldberg RM, Reid JM, Sloan JA, Atherton Skaff P, Erlichman C, Rubin J, Burch PA, Adjei AA, Alberts SA, Schaaf LJ, Elfring G, Miller LL. (2000). Phase I dose-finding and pharmacokinetic trial of Irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clinical Cancer Research 6:2236-2244.

79. Frost MH, Schaid DJ, Sellers TA, Slezak JM, Arnold PG, Woods JE, Petty PM, Johnson JL, Sitta DL, McDonnell SK, Rummans TA, Jenkins RB, Sloan JA, Hartmann LC. (2000). Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 284:319-324.

78. Weitz JJ, Marschke, Jr. RF, Sloan JA, Grill JP, Jett JR, Knost JA, Hatfield AK, Zenk DW, Bate WW, Schaefer PL. (2000). A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. Lung Cancer 28:157-162, 2000.

77. Sloan JA, Novotny PJ, Loprinzi CL. (2000). Design and analysis of cancer control studies using the SAS system. SUGI 25 Proceedings, Indianapolis, Indiana, April 9-12, 2000, pg. 259-25.

76. Adjei AA, Erlichman C, Sloan JA, Reid JM, Pitot HC, Goldberg RM, Peethambaram P, Atherton P, Hanson LJ, Alberts SR, Jett J. (2000). Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 18:1748-1757.

75. Loprinzi CL, Zahasky KM, Sloan JA, Novotny PJ, Quella SK. (2000). Tamoxifen-induced hot flashes. Clinical Breast Cancer 1:20-24.

74. Quella SK, Loprinzi CL, Barton DL, Knost JA, Sloan JA, LaVasseur BI, Swan D, Krupp KR, Miller KD, Novotny PJ. (2000). Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol 18:1068-1074.

73. Martenson JA, Bollinger JW, Sloan JA, Novotny PJ, Urias RE, Michalak JC, Shanahan TG, Mailliard JA, Levitt R. (2000). Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy: A North Central Cancer Treatment Group Phase III Double-Blind Placebo-Controlled Trial. J Clin Oncol 18:1239-1245.

72. Adjei AA, Klein CE, Kastrissios H, Goldberg RM, Alberts SR, Pitot HC, Sloan JA, Reid JM, Hanson LJ, Atherton P, Rubin J, Erlichman C. (2000). Phase I and Pharmacokinetic Study of Irinotecan and Docetaxel in Patients With Advanced Solid Tumors: Preliminary Evidence of Clinical Activity. J Clin Oncol 18:1116-1123.

71. Bonner JA, Sloan JA, Rowland, Jr., KM, Klee GG, Kugler JW, Mailliard JA, Wiesenfeld M, Krook JE, Maksymiuk AW, Shaw EG, Marks RS, Perez EA. (2000). Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer. Clinical Cancer Research 6:597-601.

70. Jatoi A, Loprinzi CL, Sloan JA, Goldberg RM. (2000). Is ATP (Adenosine 5’-Triphosphate), like STP, a performance-enhancing additive for the tanks of cancer patients? Journal of the National Cancer Institute 92:290-291.

69. Adjei AA, Erlichman C, Davis JN, Cutler DL, Sloan JA, Marks RS, Hanson LJ, Svingen PA, Atherton P, Bishop WR, Kirschmeier P, Kaufmann SH. (2000). A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity. Cancer Research 60:1871-1877.

68. Lobchuk MM, Kristjanson L, Degner L, Blood P, Sloan JA. (1999). Wahrnehmung der Symptombelastung bei Lungenkrebspatienten: I. Ubereinstimmung zwischen Patienten und den sie hauptsachlich pflegenden Angehorigen. Pflege 12:352-361.

67. Weitz JJ, Marschke, Jr., RF, Sloan JA, Grill JP, Jett JR, Knost JA, Hatfield AK, Zenk DW, Bate WW, Schaefer PL. (Accepted, 2000). A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. Lung Cancer 28(2):157-162, 2000.

66. Anderson PM, Markovic SN, Sloan JA, Clawson ML, Wylam M, Arndt CAS, Smithson WA, Burch P, Gornet M, Rahman E. (1999). Aerosol granulocyte macrophage-colony stimulating factor: A low toxicity, lung-specific biological therapy in patients with lung metastases. Clinical Cancer Research 5:2316-2323.

65. Loprinzi CL, Johnston PB, Sloan JA, Novotny P, Ellison N. (1999). Have medical oncologists recently modified surveillance testing patterns for melanoma and/or breast cancer survivors? Cancer Research Therapy and Control 9:205-214.

64. Sloan JA, Loprinzi CL, Novotny PJ, Okuno S, Nair S, Barton DL. (2000). Sex differences in Fluorouracil-induced stomatitis. Journal of Clinical Oncology 18:412-420.

63. Wagner JL, Alberts SR, Sloan JA, Cha S, Killian J, O’Connell MJ, Van Grevenhof P, Lindman J, Chute CG. (1999). Incremental costs of enrolling cancer patients in clinical trials: A population-based study. J Natl Cancer Inst 91:847-853.

62. Fonseca R, O’Neill BP, Foote RL, Grill JP, Sloan JA, Frytak S. (1999). Cerebral toxicity in patients treated for small cell carcinoma of the lung. Mayo Clin Proc 74:461-465.

61. Bonner JA, Sloan JA, Shanahan TG, Brooks BJ, Marks RS, Krook JE, Gerstner JB, Maksymiuk A, Levitt R, Mailliard JA, Tazelaar HD, Hillman S, Jett JR. (1999). Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 17:2681-2691.

60. Bretscher M, Rummans T, Sloan JA, Kaur J, Bartlett A, Borkenhagen L, Loprinzi C. (1999). Quality of life in hospice patients - A Pilot Study. Psychosomatics 40:309-313.

59.  Okuno SH, Woodhouse CO, Loprinzi CL, Sloan JA, LaVasseur BI, Clemens-Schutjer D, Swan D, Axvig C, Ebbert LP, Tria Tirona MRB, Michalak JC, Pierson N. (1999). Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fuorouracil (5-FU)-based chemotherapy. American Journal of Clinical Oncology 22:258-261.

58. Sloan JA, Cha SS, Wagner JL, Albert SR, Lindman J, Allmer C. (1999). Analyzing oncology patient health care costs using the SAS system. Proceedings of SUGI 24, 1540-1545.

57. Mandrekar J, Sargent DJ, Novotny PJ, Sloan JA. (1999). A general Gibbs sampling algorithm for analyzing linear models using the SAS system. Proceedings of SUGI 24, 1644-1649.

56. Pitot HC, McElroy EA, Jr., Reid JM, Windebank AJ, Sloan JA, Erlichman C, Bagniewski PG, Walker DL, Rubin J, Goldberg RM, Adjei AA, Ames MM. (1999). Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clinical Cancer Research 5:525-531.

55. Galanis E, Frytak S, Rowland K, Sloan JA, Lennon VA. (1999). Neuronal autoantibody titers in the course of small cell lung carcinoma and platinum associated neuropathy. Cancer Immunol Immunother 48:85-90.

54. Sloan JA, Nemecek AM, Blood P, Scott-Findlay S, Trylinski C, Whittaker H, El Sayed S, Clinch J, Khoo J. (Accepted, August, 1998). The trajectory of cancer patients through the Manitoba health care system. I. Framing the research question. Cancer Prevention and Control.

53. Sloan JA, Nemecek AM, Blood P, Scott-Findlay S, Trylinski C, Whittaker H, El Sayed S, Clinch J, Khoo J. (Accepted, August, 1998). The trajectory of cancer patients through the Manitoba health care system. II. Methodology and basic findings. Cancer Prevention and Control.

52. Sloan JA, Scott-Findlay S. (Accepted, August, 1998). The trajectory of cancer patients through the Manitoba health care system. III. Developing a staging methodology. Cancer Prevention and Control.

51. Loprinzi CL, Kugler JW, Sloan JA, Rooke TW, Quella SK, Novotny P, Mowat RB, Michalak JC, Stella PJ, Levitt R, Tschetter LK, Windschilt H. (1999). Lack of Effect of Coumarin in Women with Lymphedema after Treatment for Breast Cancer. New England Journal of Medicine 346-350.

50. Goodridge DM, Sloan JA, LeDoyen YM, McKenzie J, Knight WE, Gayari M. (1998). Risk assessment scores, prevention strategies and the incidence of pressure ulcers among the elderly in four Canadian health care facilities. Canadian Journal of Nursing Research 30:23-44.

49. Sargent DJ, Sloan JA, Cha S. (1999). Sample size and design considerations for phase II clinical trials with correlated observations. Controlled Clinical Trials 20:242-252.

48. Marschke RF, Grill, J.P., Sloan, J.A., Wender, D.B., Levitt, R., Mailliard, J.A., Gerstner, J.B., Ghosh, C., Morton, R.F., Jett, J.R. Phase II Study of High-Dose Somatostatin Analogue in Patients either Previously Treated or Untreated who have Extensive-Stage Small Cell Lung Cancer. (1999). American Journal of Clinical Oncolog 22:15-17.

47. Sloan JA, O’Fallon JR, Suman VJ, Sargent DJ. (1998). Incorporating quality of life measurement in oncology clinical trials. Proceedings of the American Statistical association 282-287.

46. Loprinzi CL, Pisansky TM, Fonseca R, Sloan JA, Zahasky KM, Quella SK, Novotny PJ, Rummans TA, Dumesic DA, Perez EA. (1998). Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 16:2377-2381.

45. Alberts SR, Erlichman C, Reid JM, Sloan JA, Ames MM, Richardson RL, Goldberg RM.(1998). Phase I study of the duocarmycin semi-synthetic derivative KW-2189 given daily for 5 days every 6 weeks. Clinical Cancer Research 4:2111-2117.

44. Degner LF, Davison J, Sloan JA, Mueller B. (1998). Development of a scale to measure information needs in cancer care. Journal of Nursing Measurement 6:137-153.

43. Atherton Skaff P, Sloan JA. (1998). Design and analysis of equivalence trials via the SAS system. Proceedings of SUGI 23, 1166-1171. (best paper award)

42. Sloan JA, Novotny PJ, Loprinzi CL. (1998) Analyzing quality of life data via the SAS system. Proceedings of SUGI 23, 1213-1222.

41. Barton DL, Loprinzi CL, Quella SK, Sloan JA, Veeder MH, Egner JR, Fidler P, Stella PJ, Swan DK, Vaught NL, Novotny P. (1998) Prospective evaluation of vitamin E for hot flashes in breast cancer. Journal of Clinical Oncology 16:495-500.

40. Quella SK, Loprinzi CL, Sloan JA, Vaught NL, DeKrey WL, Fischer T, Finck G, Pierson N, Pisansky TM. (1998). Long-term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer 82:1784-1788.

39. Finck G, Barton D, Loprinzi CL, Quella S, Sloan JA. (1998). Definitions of hot flashes in breast cancer survivors. Journal of Pain and Symptom Management 16:327-333.

38. Bonner JA, McGinnis WL, Stella PJ, Marschke RF, Sloan JA, Shaw EG, Maillard JA, Creagan, E.T., Ahuja, R.K, Johnson, P.A. (1998). The Possible advantage of hyperfractionated thoracic radiotherapy in locally advanced non-small cell lung cancer: results of a north central cancer treatment group phase III study. Cancer 82:1037-1048.

37. Degner L, Sloan JA, Venkatesh P. (1997). The control preferences scale. Canadian Journal of Nursing Research 29:21-43.

36. Goldberg RM, Reid JM, Ames MM, Sloan JA, Rubin J, Erlichman C, Kuffel MJ, Fitch TR. A phase I and pharmacologic trial of fazarabine (Ara-AC) with G-CSF. Clinical Cancer Research 3:2363-2370, 1997.

35. Sloan JA, Loprinzi CL, Kuross SA, Miser AW, O’Fallon JR, Mahoney MR, Heid IM, Bretscher ME, Vaught, NL. (1998). Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. Journal of Clinical Oncology 16:3662-3673.

34. Chalmers KI, Bramadat IJ, Sloan JA. (1997). Development and testing of the primary health care questionnaire (PHCQ): Results with students and faculty in diploma and degree nursing programs. Canadian Journal of Nursing Research 29:79-96.

33. Colon-Otero G, Marschke R, Camoriano JK, Sorensen JM, Sloan JA, Richardson RL. (1997). A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas. The Cancer Journal from Scientific American 3: 297-302.

32. Degner LF, Kristjanson LJ, Bowman D, Sloan JA, Carriere KC, O’Neil J, Bilodeau B, Watson P, Mueller B. (1997). Information needs and decisional preferences in women with breast cancer. JAMA 277(18):1485–92.

31. Ellison N, Kugler J, Hatfield A, Miser A, Sloan JA, Wender D, Rowland K, Molina R, Cascino T, Vukov A, Dhaliwal H, Ghosh C. (1997). Phase III placebo-controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients. Journal of Clinical Oncology 15(8):2974–80.

30. Lobchuk MM, Kristjanson L, Degner L, Blood P, Sloan JA. (1997). Perceptions of symptom distress in lung cancer patients: I.Congruence between patients and primary family caregivers. Journal of Pain & Symptom Management 14(3):136–46.

29. Loprinzi CL, Abu-Ghazale S, Sloan JA, vanHaelst-Pisani C, Hammer AM, Rowland KM, Law M, Windschitl HE, Kaur JS, Ellison N. (1997). Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. Journal of Clinical Oncology 15: 969-973.

28. McGinnis W, Loprinzi CL, Buskirk S, Sloan JA, Drummond R, Frank A, Shanahan T, Kahanic S, Moore R, Schild S, Humphrey S. (1997). Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis. Journal of Clinical Oncology 15: 1239-1243.

27. Loprinzi CL, Kugler J, Sloan JA. (1997). Coumarin-Induced Hepatotoxicity. Letter-to-the-Editor, Journal of Clinical Oncology 15(9):3167–8.

26. Loprinzi CL, Ghosh C, Camoriano J, Sloan JA, Steen PD, Michalak JC, Schaefer PL, Novotny PJ, Gerstner JB, White DF, Hatfield AK, Quella SK. (1997). Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving Fluorouracil-based chemotherapy. Journal of Clinical Oncology 15: 1235-1238.

25. Okuno S, Foote R, Galavita S, Sloan JA, Earle J, Novotny P, Burk M, Frank A. (1997). A Randomized Trial of a Nonabsorbable Antibiotic Lozenge for Alleviation of Radiation-Induced Mucositis. Cancer 79: 2193-2199.

24. Perez EA, Sloan JA, Owens DT, Novotny PJ, Bonner JA. (1997). Utility of screening procedures for detecting recurrence of disease following complete response in patients with small cell lung cancer. Cancer 80(4):676–80.

23. Sloan JA, Novotny P, Loprinzi CL, Ghosh M. (1997) Graphical and Analytical Tools for Two-Period Crossover Clinical Trials. SUGI proceedings 22:1312-1317. (best paper award)

22. Beaver K, Luker KA, Owens RG, Leinster SJ, Degner LF, Sloan JA. (1996). Treatment decision making in women newly diagnosed with breast cancer. Cancer Nursing 19(1):8–19.

21. Kristjanson LJ, Sloan JA, Dudgeon D, Adaskin E. (1996). Family members’ perceptions of palliative cancer care: Predictors of family functioning and family members’ health. Journal of Palliative Care 12(4): 10-20.

20. Degner L, Sloan JA. (1995). Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. Journal of Pain and Symptom Management 10: 1-8.

19. Luker KA, Beaver K, Leinster S, Owens RG, Degner L, Sloan JA. (1995). The information needs of women newly diagnosed with breast cancer. Journal of Advanced Nursing, 22: 134-141.

18. Sloan JA, Schwarz C, Neden L. (1995). Dataset on silver-maple-tree growth regulators. Journal of the Statistical Society of Canada Vol. 23 No. 3: 325-329.

17. Trylinski C, Sloan JA, Nemecek A. (1995). Cancer Patient trajectory through the Manitoba Health care system. Journal of the National Cancer Registrars Association 21: 31-34.

16. Kraut A, Sloan JA, Silviu-Dan F, Peng Z, Gagnon D, Warrington R. (1994). Occupational allergy after exposure to caddis flies at a hydroelectric power plant. Occupational and Environmental Medicine 51: 408-413.

15. Paterson B, Sloan JA. (1994). A phenomenological study of decision-making experience of individuals with long-standing diabetes. Journal of Diabetes Care 18: 10-19. (1995 Diabetes manuscript of the year award)

14. Sloan JA. (1994). Laypersons guide to professional titles in statistics. Chance 7: 33.

13. Sloan JA. (1994). Statistical consulting is scholarship, too. Journal of the American Statistical Association 48: 62-63.

12. Degner, LF, Sloan, JA. Decision making during serious illness: what role do patients really want to play? Journal Clin Epidemiol, Vol. 45 No. 9: pp 941-950, 1992

11. Gregory, D, Russell, C , Hurd, J, Tyance, J, Sloan, J. Canada’s Indian Health Transfer Policy: The Gull Bay Band Experience, Human Organization, Vol 51 No. 3, pp 214- 222, 1992

10. Heaman M, Beaton J, Gupton A, Sloan JA. (1992). A comparison of childbirth expectations in high risk and low risk pregnant women. Journal of Clinical Nursing Research 1: 252-265.

9. Schwarz C, Sloan JA, Neden L, Brewster, JF. (1992). Analysis of a multiple sclerosis dataset. Journal of the Statistical Society of Canada 20: 91-108.

8. Sloan JA. (1998) How to Consult with Statistician – and Live

7. Development of a staging system for chemotherapy-induced stomatitis. Cancer Nursing, Vol 14 (1): pp 6-12, 1991.

6. Gupton, A, Besaton, J, Sloan J, Bramadat, I.. The development of a scale to measure childbirth expectations. The Canadian Journal of Nursing Research, vol 23 (2): PP 35-47, Summer 1991.

5. Kristjanson L, Sloan JA. (1991). Evaluation of the grief experience for surviving family members. Journal of Palliative Care 7: 51-56.

4. Sloan JA, Sinha SK. (1991). Bayesian prediction intervals for a mixture of exponential failure-time distributions for complete and censored samples. Statistics and Probability Letters 11: 537-545.

3. Scruby L, Sloan JA. (1989). Evaluation of bereavement intervention. Canadian Journal of Public Health 80: 394-398.

2. Sinha SK, Sloan JA. (1989). Prediction intervals for a mixture of Weibull failure-time distributions - a Bayesian approach. South African Journal of Statistics 23: 119-130.

1. Sinha SK, Sloan JA. (1988). Bayes estimation of the parameters and reliability function of the three-parameter Weibull distribution. IEEE Transactions on Reliability 37: 364-369.

SUBMITTED TO REFEREED JOURNALS (REVIEW PENDING)

3. Kluka S, Kristjanson L, Sloan J. (submitted September 1999). Measuring ostomy-related concerns of cancer patients and their partners. Journal of Nursing Measurement.

2. Gupton A, Goodridge D, Loewen L, Sloan J. (submitted February 1999). Preventing pressure ulcers: A multi-site outcome-based research utilization project.

1. Dean A, Blight J, Kristjanson L, Sloan JA, Dickenson AH, Underwood R. (submitted May, 1997). Multi-drug therapy for neuropathic pain. Journal of Pain and Symptom Management.